Table S1: Association of subsequent treatments with covariates using multinomial regression

|  |  |  |  |
| --- | --- | --- | --- |
|  | Taxane group |  | S-1 group |
|  | OR\* (95% CI) | OR† (95% CI) |  | OR\* (95% CI) | OR† (95% CI) |
| Age  |  |  |  |  |  |
|  < 65 vs ≥65 | 1.61 (0.70–3.67) | 0.69 (0.29–1.56) |  | 1.35 (0.65–2.77) | 1.05 (0.48–2.28) |
| Hormone receptor status |  |  |  |  |  |
|  ER + and/or PgR + vs other  | 0.54 (0.17–1.55) | 0.52 (0.16–1.64) |  | 0.77 (0.29–1.98) | 0.78 (0.27–2.25) |
| Live metastasis |  |  |  |  |  |
|  Yes vs No | 1.55 (0.75–3.29) | 0.92 (0.41–2.07) |  | 1.83 (0.93–3.69) | 1.40 (0.64–3.05) |
| Disease free interval |  |  |  |  |  |
|  < 2 years vs other | 1.51 (0.60–3.99) | 0.71 (0.24–2.06) |  | 1.90 (0.78–4.77) | 2.38 (0.95–6.15) |
| Lymph node metastasis |  |  |  |  |  |
|  0–3 vs other | 0.88 (0.42–1.83) | 0.92 (0.41–2.03) |  | 0.34 (0.17–0.65) | 0.60 (0.28–1.27) |
| (Neo) adjuvant therapy |  |  |  |  |  |
|  Taxane | 0.69 (0.31–1.56) | 0.77 (0.32–1.84) |  | 0.42 (0.19–0.87) | 1.00 (0.45–2.21) |
|  Oral fluoropyrimidine  | 0.72 (0.28–1.92) | 0.65 (0.22–1.84) |  | 2.32 (0.87–6.60) | 1.36 (0.42–4.28) |
|  Endocrine therapy | 0.93 (0.38–2.28) | 1.30 (0.49–3.46) |  | 0.57 (2.50–1.27) | 0.52 (0.21–1.30) |
| Recent ECOG PS |  |  |  |  |  |
|  0 vs ≥ 1 | 1.28 (0.62–2.62) | 1.38 (0.64–2.98) |  | 0.83 (0.40–1.71) | 0.72 (0.33–1.58) |
| Progression Status |  |  |  |  |  |
|  Yes vs No | 1.77 (0.79–3.95) | 2.12 (0.89–5.10) |  | 2.05 (0.76–5.71) | 3.07 (1.04–9.90) |
| Withdrawal by adverse events |  |  |  |  |  |
|  Yes vs No | 0.73 (0.33–1.63) | 0.41 (0.17–0.99) |  | 1.17 (0.36–3.92) | 5.85 (1.89–20.0) |

\*Ratio of odds of receiving crossover treatment, relative to other treatment. †Ratio of odds of receiving protocol-recommended treatment, relative to other treatment. OR; odds ratio, CI; confidence interval, ER; oestrogen receptor, PgR; progesterone receptor, ECOG PS; Eastern Cooperative Oncology Group performance status.